TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24220487
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg gabapentin (group B)
Study: 24220487
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg chlorpromazine (group C)
Study: 24220487
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dexamethasone (group D)
Study: 15049988
Drug: Intravesical resiniferatoxin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical resiniferatoxin (maximum dose of 1 micro mol/L)
Study: 9149606
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 1,200 mg/d for 4 days prior to exposure and 400 mg on exposure day
Study: 9149606
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) for 4 days prior to exposure and 400 mg on exposure day
Study: 2506661
Drug: rt-PA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (100 mg on day 1, 50 mg on day 2) plus heparin
Study: 2506661
Drug: rt-PA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (50 mg over 8 hours on days 1 and 2) plus heparin
Study: 2506661
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (rt-PA plus heparin)
Study: 30555009
Drug: Sedentary individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedentary individuals (regular vigorous exertion <1 day weekly)
Study: 30555009
Drug: Frequent regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent regular vigorous physical exertion (>4 days weekly)
Study: 28931647
Drug: Dextromethorphan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (various doses)
Study: 23436259
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg zaleplon
Study: 23436259
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg zaleplon
Study: 23436259
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg zaleplon
Study: 23436259
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zaleplon
Study: 23436259
Drug: Zaleplon (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon (all doses)
Study: 21458802
Drug: Intracytoplasmic morphologically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic morphologically selected sperm injection
Study: 19151570
Drug: Epirubicin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin preparation (FarmorubicinRTU)
Study: 19151570
Drug: Lyophilized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized formulation of epirubicin (Farmorubicin)
Study: 15059413
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg, 20 mg, and 10 mg per day for 4 weeks)
Study: 15059413
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii multiglycoside (TW, 30-60 mg per day)
Study: 15059413
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA, 5-6 mg per kilogram of body weight per day)
Study: 15059413
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF, 16-18 mg per kilogram of body weight per day)
Study: 15059413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-thyroid drugs and levo-thyroxine)
Study: 10989721
Drug: Pefloxacin (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (15-20 mg/kg per day bid for 14-28 days) in combination with ceftazidime and amikacin
Study: 9315494
Drug: Trazodone 150
Normalized name: traZODone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 150 mg/d
Study: 3512419
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir for 42 days
Study: 3512419
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir for five days followed by placebo for 37 days
Study: 30527775
Drug: Enoxaparin–warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin–warfarin
Study: 26916095
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with exemestane plus bevacizumab (E + BEV)
Study: 24378269
Drug: Cyanoacrylate injection
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanoacrylate injection (GVO)
Study: 20959009
Drug: Diabetes-specific cognitive
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes-specific cognitive behaviour group therapy
Study: 8404175
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy
Study: 12507187
Drug: High-dose routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose routine therapies
Study: 2692969
Drug: Etizolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etizolam (0.5 mg twice daily for 5 weeks)
Study: 2692969
Drug: Alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5 mg twice daily for 5 weeks)
Study: 29955136
Drug: XELIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELIRI regimen (irinotecan 180 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1-10 of a 14-day cycle)
Study: 29955136
Drug: Irinotecan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan monotherapy (irinotecan 180 mg/m2 on day 1 of a 14-day cycle)
Study: 17998441
Drug: Daily patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily patient reminder to document seizures
Study: 12468958
Drug: Controlled-release budesonide
Normalized name: budesonide Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release budesonide (4.5 mg)
Study: 12468958
Drug: Deuterium-labelled standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterium-labelled standard formulation (4.8 mg)
Study: 12468958
Drug: Controlled-release budesonide
Normalized name: budesonide Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release budesonide
Study: 12468958
Drug: Deuterium-labelled standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterium-labelled standard formulation
Study: 7710409
Drug: Conventional mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mandibular block injection
Study: 27856497
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered ischemia-tolerant MSCs (itMSCs) at a dosage of 1.5×10^6 cells/kg
Study: 27856497
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered ischemia-tolerant MSCs (itMSCs)
Study: 23512917
Drug: PGX (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGX (15 g day(-1) for 14 weeks)
Study: 19186713
Drug: Acupuncture twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture twice each day (observation group I)
Study: 19186713
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received same Chinese drugs and western medicine and electroacupuncture at Jiquan (HT 1), Quchi (LI 11), Hegu (LI 4), Huantiao (GB 30)
Study: 17577686
Drug: Amyloid A
Normalized name: Amyloid A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amyloid A protein quantification in fat tissue using ELISA with monoclonal antihuman serum amyloid A antibodies.
Study: 15464679
Drug: Eptifibatide infusion
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide infusion
Study: 9752892
Drug: Lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5 to 10 mg)
Study: 7042592
Drug: Ambroxol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (1000 mg/day for 5 days)
Study: 31419544
Drug: Crisaborole ointment
Normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crisaborole ointment 2% applied twice daily for 14 days
Study: 31419544
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied twice daily for 14 days
Study: 31419544
Drug: Crisaborole ointment
Normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crisaborole ointment 2% applied open-label to all affected areas for 28 days after initial treatment
Study: 31419544
Drug: Crisaborole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole treatment
Study: 22464008
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily supportive text messages (n=26)
Study: 20372874
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (NaCl, 100 mmol/24 h) supplementation during telmisartan treatment
Study: 20372874
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during telmisartan treatment
Study: 15934129
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (13 weeks duration)
Study: 10588467
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil (20 g per day for 42 days)
Study: 10588467
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil (20 g per day for 42 days)
Study: 9432569
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate (100 mg b.i.d.)
Study: 9432569
Drug: Mesoglycan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan (50 mg b.i.d.)
Study: 1541143
Drug: Theophylline (Uniphyllin)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (Uniphyllin) 800 mg taken at night for four weeks
Study: 4021762
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with intensive preoperative irradiation
Study: 29935909
Drug: General Education
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Education DVD on chemotherapy side effects (GE‐DVD)
Study: 20124256
Drug: Acetylcholinesterase inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase inhibitors (AChIs)
Study: 20124256
Drug: FDA-approved AD
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved AD or psychiatric medications
Study: 17646220
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg/d)
Study: 7557205
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (ethinylestradiol 50 micrograms/d for 7 days, ethinylestradiol 50 micrograms and desogestrel 125 micrograms/d for 15 days)
Study: 7557205
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ethinylestradiol 50 micrograms and levonorgestrel 250 micrograms/d for 21 days (Group 1, n = 24)
Study: 7557205
Drug: Lynestrenol 10
Normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol 10 mg/d continuously (Group 2, n = 14)
Study: 7557205
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 3, n = 21)
Study: 9494149
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole
Study: 28179586
Drug: Preoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concurrent chemoradiotherapy (Pre-S CRT, weekly cisplatin 30mg/m2)
Study: 19663522
Drug: Armodafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (200 mg/day)
Study: 15486518
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75-150 mg/day
Study: 11573599
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5.5 microg kg(‐1))
Study: 7847600
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nalmefene
Study: 7847600
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nalmefene
Study: 2841885
Drug: Fentanyl-group: approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl-group: approximately 0.2 mg/h fentanyl, 2.5 mg/h midazolam, 2 mg/h pancuronium in intermittent doses
Study: 2841885
Drug: Ketamine-group: about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine-group: about 50 mg/h ketamine and 2.5 mg/h midazolam, 2 mg/h pancuronium
Study: 31718828
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg/day)
Study: 31718828
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg/day) and Rosiglitazone (4 mg/day)
Study: 23420231
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus rescue medication (cetirizine)
Study: 23420231
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture plus rescue medication (RM)
Study: 15557392
Drug: Progressive increases
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive increases in salt intake from 10 to 250 mmol/d by a daily amount of 50 mmol
Study: 10372794
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity cognitive‐behavioral therapy
Study: 10372794
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity therapy
Study: 1816196
Drug: norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin 400 mg bid for 10 days
Study: 1816196
Drug: amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 500 mg bid plus tinidazole 500 mg bid for 15 days
Study: 1816196
Drug: colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: colloidal bismuth subcitrate (CBS) 240 mg bid for 4 weeks
Study: 27988427
Drug: CBT-SAD (social
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-SAD (social anxiety specific cognitive behavioral therapy)
Study: 27988427
Drug: CBT-GEN (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-GEN (generic cognitive behavioral therapy)
Study: 23620930
Drug: Flying needling
Normalized name: house fly extract
DrugBank: Musca domestica (DB10688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flying needling therapy
Study: 15704053
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg 3 times daily
Study: 8411611
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice a day
Study: 31914075
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate with a split-dose of PEG plus ascorbic acid
Study: 28573932
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR maintained at 1.5 to 2.0) in group A
Study: 28573932
Drug: Standard-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity warfarin (INR maintained at 2.0 to 2.5) in group B
Study: 17598506
Drug: Prophylactic vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic vaccines for primary prevention
Study: 15076015
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg for 2 weeks
Study: 12705512
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg slow-release caffeine
Study: 3276409
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (IVSK)
Study: 26320523
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg intravenously + Metoclopramide 10 mg intravenously
Study: 26320523
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Metoclopramide 10 mg intravenously
Study: 18951860
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch (LP) applied on the anterior abdominal wall
Study: 18951860
Drug: No lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No lidocaine patch applied
Study: 16128595
Drug: 50 mg/mL
Normalized name: urea 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/mL oral suspension
Study: 16128595
Drug: 200mg tablets
Normalized name: allopurinol 200 MG / lesinurad 200 MG [Duzallo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg tablets
Study: 16128595
Drug: 800mg tablets
Normalized name: piracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg tablets (reference)
Study: 2571114
Drug: Dipivefrin hydrochloride
Normalized name: Dipivefrin Hydrochloride
DrugBank: Dipivefrin (DB00449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipivefrin hydrochloride 0.1% twice daily
Study: 31960907
Drug: ICSI (Intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICSI (Intracytoplasmic Sperm Injection)
Study: 31654580
Drug: Bar implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar implant overdentures (BOD)
Study: 31654580
Drug: Resilient telescopic
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resilient telescopic implant overdentures (TOD)
Study: 31654580
Drug: Stud implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stud implant overdentures (SOD)
Study: 31586772
Drug: Melatonin 25
Normalized name: calcium phosphate/melatonin 250 mg-1.5 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 25 mg administered 1 hour before bedtime for 12 weeks
Study: 31586772
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour before bedtime for 12 weeks
Study: 28342282
Drug: Immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tacrolimus (IR-TAC)
Study: 28342282
Drug: Extended-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tacrolimus (ER-TAC)
Study: 21777634
Drug: Low viscous
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low viscous alginate fibre‐based preloads of 3% concentration (500 ml volume) three times a day
Study: 17980952
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN) vaginal gel 80 mg
Study: 17980952
Drug: Misoprostol vaginal
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol vaginal gel 200 microg
Study: 16894289
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy (chemotherapy + radiotherapy)
Study: 16894289
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including gemcitabine
Study: 16894289
Drug: Positron emission
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography after one or two cycles of chemotherapy
Study: 12660125
Drug: Chlorhexidine-based product
Normalized name: chlorhexidine Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-based product (0.3% concentration); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Study: 12660125
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (amine-stannous fluoride combination); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Study: 12660125
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (amine-stannous fluoride combination); separate analysis for patients with <1000 leucocytes/microL for a minimum of three days
Study: 1469516
Drug: Liquid supplement
Normalized name: Clear liquid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid supplement (LS)
Study: 29468748
Drug: Test diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test diet (0.8 g protein kg‐1 body weight: 35% animal proteins, 35% soy protein, 30% vegetable proteins)